Kornimate/medical-research-clean huggingface dataset:
impact of coronary images used during patient education on coronary artery disease and subsequent lifestyle modifications. is a picture really worth a thousand words?

Conditions: Coronary Artery Disease

Summary: subjects in this research study have coronary artery disease (cad). this occurs when there is a build-up of fatty material in the wall of the heart arteries that causes narrowing of the arteries. this could lead to chest pain, a heart attack, weakening of the heart and/or permanent damage to the heart. as part of their normal routine care, subjects had or will have a percutaneous coronary intervention (pci) to restore the blood flow in the arteries of their heart. during a pci procedure, pictures are taken of the arteries before and after the treatment of the narrowing in the arteries. these pictures are acquired through angiography which is a way to produce x-ray pictures of the inside of arteries. after a pci procedure, there is a possibility for narrowing of the arteries to return. the likelihood of this happening can be greatly reduced by lifestyle changes and adhering to heart medication regimens. it is part of normal, routine care for cad patients to be given written and verbal information on how to lead a heart healthy lifestyle and to take heart medications properly. in this research study, the investigators will show half of the patients their before and after images of their heart arteries where the narrowing occurred and was treated. the other half of the patients will not be shown these images. both groups will still receive information about lifestyle and medications as part of their normal, routine care. at the end of this study, the investigators will compare both groups to see if there are any differences in making lifestyle changes and taking heart medications properly. additionally, the investigators would also like to see if there are any resulting differences in the amount of hearts attacks or other heart related medical events.


Eligibility criteria:
inclusion criteria: 1. over the age of 18 2. able to provide informed consent in english. 3. undergoing percutaneous coronary intervention for any clinical indication. exclusion criteria: 1. patients not able to provide informed consent. 2. patients without a means for telephone communication. 3. incarcerated individuals and other special populations. 4. patients unable to or unwilling to reliably participate in telephone followup. 5. significant neurologic co morbidities such as cerebrovascular accidents with deficit or developmental delays which may impact learning and/or memory 6. any medical comorbidity which might result in life-expectancy \< 1 year 7. any other condition of sufficient severity to impair cooperation in the study- i.e. substance abuse, etc.

Keywords: patient education coronary artery disease impact of coronary images used during patient education on coronary artery disease and subsequent lifestyle modifications.
copd aerosol study comparing the efficacy of nebulizers versus dry powder inhalers

Conditions: COPD Exacerbation

Summary: the purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (dpi) in patients recovering from severe exacerbations of copd. this is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting.


Eligibility criteria:
inclusion criteria: * current or past cigarette smoking history of \>/= 10 pack-years. * fev1/fvc ratio \</= 70%. * known diagnosis of copd. * current hospitalization for a primary diagnosis of acute exacerbation of copd. * must be able to understand and willing to sign an informed consent document. exclusion criteria: * on a ventilator or mask ventilation. * allergy or contraindication to formoterol use. * marked qtc prolongation (\> 450 ms). * liver cirrhosis or chronic renal insufficiency (serum creatinine \> 2 mg/dl). * atrial fibrillation with rapid ventricular response (heart rate \> 110 bpm) or ventricular arrhythmia (frequent pvcs, ventricular tachycardia). * acute myocardial infarction within 12 weeks of patient study registration. * known pulmonary embolism. * known or suspected lung cancer. * known neuromuscular disease, stroke with residual hemiparesis, or untreated parkinsonism * pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or sub dermal implants). * inability to understand instructions. * participation in another investigational drug clinical trial within 30 days of patient study registration.

Keywords: copd chronic obstructive pulmonary disease
can tdcs enhance efficacy of rehabilitative intervention for freezing of gait in parkinson's disease?

Conditions: Parkinson Disease

Summary: freezing of gait in parkinson's disease (pd) is a major cause of disability and falls and responds often incompletely to conventional therapy. the pathogenesis remains largely unknown and therapeutic alternatives are needed. rehabilitative interventions that consist of learning cognitive strategies with sensory cueing to prevent and to overcome fog represent the most efficacious intervention, but difficulties in learning and execution of these cognitive strategies are the main cause of failure. transcranial direct current stimulation (tdcs) enhances motor task learning and execution in patients with pd and might enhance the efficacy of rehabilitative interventions. this study intends to address the following question whether tdcs can enhance the efficacy of rehabilitative interventions in the treatment of freezing of gait in parkinson's disease?


Eligibility criteria:
inclusion criteria: * men and women aged 30 to 80 years with dopa-responsive pd hoehn and yahr (hy) grade of 2 to 4 while "off" * must be on a regimen including levodopa * total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be equal to or more than 300 milligrams per day * gait difficulties with freezing of gait as defined by mds-updrs i score ≥ 2 in fog * optimal conventional pd medication for \> 1 month prior to screening * scheduled for rehabilitative intervention for the treatment of freezing of gait exclusion criteria: * significant concurrent medical or psychiatric disease * history of seizures and epilepsy * dementia or other neurodegenerative disease (besides pd) * pallidotomy, implanted electrodes and generator for deep brain stimulation * pregnancy * surgically or traumatically implanted foreign bodies such as an implanted medical pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull or eyes (other than dental appliances or fillings) that may pose a physical hazard during tdcs. * study would cause undue risk or stress for reasons such as tendency to fall, excessive fatigue, general frailty, or excessive apprehensiveness. * significant postural instability with daily falls, inability to walk the parcours or inability to walk 10 meters. * presence of significant cognitive dysfunction as determined by montreal cognitive assessment (moca) \<20 or mentally impaired patients having no capacity to provide their own consent (the physician establishing the diagnosis and applying updrs will evaluate patient's mental capacity using conventional clinical interview). * presence of other co-morbid conditions that can contribute to gait dysfunction (orthopedic, rheumatologic, cardiac, other) * presence of clinically significant hallucinations * participation in any rehabilitation therapy for fog within the last six months prior to screening

Keywords: tdcs fog freezing of gait parkinson rehabilitation
determinants of patient delay in doctor consultation in oeso-gastric cancers

Conditions: Oesophageal Carcinoma; Gastric Adenocarcinoma

Summary: this study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.

reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary point of view. the main objective of this study is to assess whether, in oeso-gastric cancer, patient delay is linked to these sociocognitive and emotional factors, in addition to previously known factors. we intend to include in this study 300 patients with a not yet treated oeso-gastric cancer diagnosed in one of 10 health centres in the north of france region. the collected data will be analysed to underline the differences between patients who consulted a doctor earlier versus those who consulted later with a cut off at 8 weeks.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * oesophageal, oeso-gastric junction or gastric cancer non treated cancer * patient informed of his diagnosis * speak fluent french exclusion criteria: * history of cancer * psychological history * patient under guardianship- * fortuitous diagnosis of cancer
bone response to enzyme replacement in gaucher's disease

Conditions: Gaucher's Disease

Summary: the purpose of this study is to examine how the skeleton responds to repeated doses of enzyme replacement therapy in patients with type i gaucher's disease who have had their spleens removed. gaucher disease is a lysosomal storage disease resulting from glycocerebroside accumulation in macrophages due to a genetic deficiency of the enzyme glucocerebrosidase. it may occur in adults but occurs most severely in infants, in whom cerebroside also accumulates in neurons. patients with gaucher's disease experience enlargement of the liver and spleen and bone destruction. the condition is passed from generation to generation through autosomal recessive inheritance. type i is the most common form. it is a chronic non-neuronopathic form, meaning the disease does not affect nerve cells. the symptoms of type i can appear at any age. in this study patients will be divided into three groups. each group will receive different doses of enzyme replacement (ceredase). in addition, two of the three groups will also receive doses of a form of vitamin d (calcitriol). researchers believe the groups receiving vitamin d will have an improved response as compared to those patients only receiving enzyme replacement. patients in each group who respond to enzyme replacement with increases in bone density will be compared to the other treatment groups.

the purpose of this study is to examine the response of the skeleton to repeated infusions of macrophage-targeted glucocerebrosidase (ceredase (trademark) ) in splenectomized patients with type i gaucher's disease. the magnitude and rate of development of the skeletal response will be monitored non-invasively. theoretically, an enhanced response should occur in patients supplemented with pharmacologic doses of 1, 25-dihydroxyvitamin d3 (calcitriol), since calcium absorption and enzyme delivery to bone marrow macrophages should be increased in this setting. these issues will be addressed in a clinical trial that uses a modified factorial design. a total of 57 patients will be assigned to three treatment groups by block randomization. group 1: ceredase (trademark) (60 iu/kg q2wks; 0-6 months) ceredase (trademark) (30 iu/kg q2wks; 7-24 months) group 2: calcitriol (0.25-3.0 micrograms/day; 0-24 months) ceredase (trademark) (60 iu/kg q2wks; 7-12 months) ceredase (trademark) (30 iu/kg q2wks; 13-24 months) group 3: calcitriol (0.25-3.0 micrograms/day; 0-24 months) ceredase (trademark) (60 iu/kg q2wks; 0-6 months) ceredase (trademark) (30 iu/kg q2wks; 7-24 months) the number of patients responding to enzyme replacement with a significant decrease in hepatic volume and a significant increase in trabecular bone density of the lumbar spine will be compared between the treatment groups.

Eligibility criteria:
splenectomized gaucher patients. aged 18-45 who have not received enzyme therapy for at least 1 year. no patients with other illnesses (pulmonary, liver, kidney, bone, hematologic).

Keywords: bone disease calcitriol enzyme replacement therapy gaucher's disease vitamin d
a dose-escalation study of obp-801 in patients with advanced solid tumors

Conditions: Solid Tumor

Summary: this phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and pharmacokinetics of ascending doses of obp-801 in patients with advanced solid tumors.


Eligibility criteria:
patient inclusion criteria patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: * histologically or cytologically confirmed metastatic or unresectable solid tumor. * has failed treatment with all standard therapies for their malignancy. * adequate karnofsky performance status. * an expected survival of at least 3 months. * adequate organ and bone marrow function. * signed informed consent form for study participation prior to screening. patient exclusion criteria patients presenting with any of the following will be excluded in the study: * clinically significant disease as defined by the protocol. * surgical therapy or other therapies within period as defined by the protocol. * any condition that will interfere with compliance with the protocol as determined by investigator.

Keywords: hdac epigenetic histone acetylation
impact of ultrasound fetal weight estimation on obstetrical management and maternal and neonatal outcomes

Conditions: Fetal Weight

Summary: the investigators wish to study the obstetrical data of pregnant women who had an ultrasound estimation of fetal weight and who delivered at the university hospital of strasbourg over the last 20 years. these retrospectively collected data are a valuable source of scientific information since they are "real life data", currently of growing interest in the scientific community, and have a large volume and quality due to the number of years included and the variety of information collected in the computerized media records. from this study, the investigators hope not only to better understand the consequences of ultrasound screening for fetal growth, but also to improve its accuracy and to develop useful models in obstetrical decision making in order to decrease maternal and neonatal morbidity.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years of age). * female and with a single pregnancy * subject having had an ultrasound follow-up at hus between 01/01/2000 and 31/12/2021 * subject who gave birth at hus between 01/01/2000 and 12/31/2021 * subject who does not object to the reuse of her data for scientific research purposes exclusion criteria: * subject who has expressed opposition to the reuse of their data for scientific research purposes * multiple pregnancies * delivery before 24 weeks of amenorrhea * diagnosis of a malformative fetal pathology * diagnosis of fetal death in utero

Keywords: fetal weight ultrasound fetal weight obstetrical management maternal outcomes neonatal outcomes
an efs to evaluate the cguard prime™ carotid stent in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the jacobs institute is conducting a sponsor investigator study of patients ≥ 18 years to establish safety and preliminary effectiveness in treating extracranial stenosis with the cguard prime™ carotid stent in the setting as an acute ischemic stroke.

a prospective, single-arm, open-label, nonblinded efs to assess the safety and preliminary effectiveness of the cguard prime™ carotid stent in adults (18 years of age or older) with extracranial stenosis in the setting as an acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * patients ≥18-year-old; carotid stenosis with at least ≥ 50% stenosis; national institute of health stroke scale (nihss) \>/=6; and evidence of large vessel occlusion (lvo) in the anterior circulation (i.e., intracranial internal carotid artery, m1 and proximal m2) by computed tomography angiography (cta). exclusion criteria: * cannot provide consent or legally authorized representative not available to provide consent. evidence of intracranial hemorrhage on non-contrast ct or mri; aspects\<6; and any contraindication to dual antiplatelet therapy.
study comparing travoprost intraocular implants to timolol ophthalmic solution

Conditions: Glaucoma Open-angle

Summary: this is a randomized trial comparing two elution doses of the travoprost intraocular implant to timolol ophthalmic solution.

this is a randomized trial comparing two elution doses of the travoprost intraocular implant to timolol ophthalmic solution in patients with open-angle glaucoma. study assessments will include iop and medication use as well as safety parameters.

Eligibility criteria:
inclusion criteria: * open angle glaucoma exclusion criteria: * uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders. * functionally significant visual field loss, including severe nerve fiber bundle defects. * prior glaucoma surgery. * uncontrolled systemic disease, pregnant females or those planning a pregnancy. * other ocular status conditions, etc.
effect of saccharomyces cerevisiae on improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis

Conditions: Vulvo-vaginal Candidiasis

Summary: this study aims to evaluate the effect of a specific strain of saccharomyces cerevisiae on improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis. this is a randomized, double-blind, placebo-controlled study.


Eligibility criteria:
inclusion criteria: * premenopausal female patient with a clinical diagnosed vulvo-vaginal candidiasis * regularly menstruating women with normal gynaecological status * patient must use a contraception method * having given a written informed consent prior to selection * covered by health insurance system and / or in compliance with the recommendations of national law in force relating to biomedical research. exclusion criteria: * pregnancy or breast feeding. * tumors in the genital tract or beast. * hypersensitivity to the study product. * uterine or vaginal bleeding of unknown origin. * use of systemic or intravaginal antibiotic or antifungal agents in the previous 14 days. * concomitant medication with antimycotics for other diagnoses. * woman with known transmitted infections such as neisseria gonorrhoea, chlamydia trachomatis, treponema pallidum, herpes simplex, trichomonas vaginalis, human papilloma virus, hiv 1 or 2. * immunocompromised individuals. * subjects not willing to stop taking probiotics in the form of dietary supplements or convenient goods * subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development. * subject under administrative or legal supervision. * subject who participate to a previous study within 3 months.
efficacy of topical cyclosporine 0.05% in the prevention of ocular surface inflammation secondary to pterygia

Conditions: Pterygia

Summary: to determine if topical cyclosporine 0.05% bid prevents recurrent inflammation and improves comfort in eyes with pterygia.


Eligibility criteria:
inclusion criteria: * pts with symptomatic pterygia unresponsive to palliative treatment.
percutaneous device closure for significant paravalvular leakage after transcatheter or surgical valve replacement

Conditions: Cardiac Valves; Heart Valve Diseases; Valvular Insufficiency

Summary: this study evaluates the effectiveness and safety of percutaneous device closure for significant paravalvular leakage after transcatheter or surgical valve replacement.


Eligibility criteria:
inclusion criteria: * significant paravalvular leakage after transcatheter or surgical valve replacement * required treatment of paravalvular leakage due to heart failure or hemolysis * there is a formal agreement of heart team as following * predicted high-risk (sts score ≥8 or logistic euroscore ≥20% or operative mortality is ≥15%) * inoperable status due to old age or frailty * written consent exclusion criteria: * risk of valve embolization because of valve dehiscence or instability * acute myocardial ischemia (enzyme elevation, st elevation on ekg(electrocardiogram), or chest pain/discomfort) * evidence of intracardiac mass, thrombus or vegetation on transthoracic/transesophageal echocardiographic study * life expectancy less than 6 months due to non-cardiac disease * pregnant or breastfeeding

Keywords: paravalvular leak
autologous platelet-rich plasma cream for photoaging and chronological skin aging

Conditions: Chronological Aging of Skin; Photoaging of Skin

Summary: human skin undergoes some morphological changes with the effects of chronological aging and photoaging, these are especially remarkable in the facial skin. changes in pigmentation, sallowness, deep wrinkling, laxity and elastosis are the main changes seen in photoaging and chronologic aging of skin. with the increasing demand, it needs to provide new approach for the prevention and treatment of these morphological changes. fibroblasts have a key role on skin aging. it is known that platelet rich plasma activates the fibroblasts and increases the synthesis of collagen and other type of matrix components. because of these specialities, platelet rich plasma is thought to be effective on skin aging.

clinical evaluation of the patients will be done for five times during 3 months. 0th day (basal), 7th day, 15th day, 45th day and 105th day.

Eligibility criteria:
inclusion criteria: * the patient has periorbital wrinkles with glogau scale 3 or more exclusion criteria: * patients with precancerous lesions * patients with inflammatory skin disease like rosacea, psoriasis, seborrheic eczema * patients with connective tissue disease like lupus erythematosus * patients have a cosmetic intervention to their face, like chemical peel, infrared, radio frequency, laser, fillers or botulinum toxin injections in last 6 months * patients who use an anti aging cream containing retinoic acid, vitamin c and peptides in last 3 months * pregnant or lactating females

Keywords: platelet rich plasma
evaluation of the ulthera system for treating axillary hyperhidrosis

Conditions: Axillary Hyperhidrosis

Summary: to evaluate the ulthera system and the 7-3.0mm transducer for treating axillary hyperhidrosis.


Eligibility criteria:
inclusion criteria: * male or female, age 18-75 years. * diagnosis of bilateral axillary hyperhidrosis refractory to previous topical therapies. * at least 50 mg of spontaneous resting axillary sweat production in each axilla measured gravimetrically at room temperature/humidity (20 - 25.6°c/20-80%) over a period of 5 minutes. (patients should be at rest for at least 30 minutes after physical exercise including walking.) * hdss score of 3 or 4. an attempt will be made to approximate an equal number of scores 3 and 4. * willingness to refrain from use of aspirin, ibuprofen, naproxen or any other nsaid, and vitamin e in the 2 weeks prior to each study treatment . exclusion criteria: * dermal disorder including infection at anticipated treatment sites in either axilla. * previous botulinum toxin treatment of the axilla in the past year. * expected use of botulinum toxin for the treatment of any other disease during the study period. * known allergy to starch powder, iodine, lidocaine, or epinephrine. * secondary hyperhidrosis, for example, hyperhidrosis that is secondary to other underlying diseases including hyperthyroidism, lymphoma and malaria. * previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage and ultrasonic surgery.